News

Rare Disease Biotech Innovators Urge Timely Reauthorization of Rare Pediatric Disease Priority Review Voucher (PRV) Program

Washington, DC – On September 12, the Rare Disease Company Coalition sent a letter to Congressional leadership urging them to support the swift passage of S.4583/H.R. 7384, the Creating Hope Reauthorization Act of 2024.

The bill would reauthorize the rare pediatric disease priority review voucher (PRV) program, a proven policy that has benefitted hundreds of thousands of patients living with a rare disease. Over the past 12 years, the program has been an innovation-driving and cost-effective policy that spurs research & development (R&D) in rare pediatric diseases.

If Congress allows it to expire on September 30, this critical program will be out of reach for many rare disease treatments. 

Read the full letter below.

Click here to download.